Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance
Published version of a preprint
The DOI matches its Crossref record; 49 of the 55 references it cites were found in a registry or an index.
Abstract
DNA-damaging anticancer drugs remain a part of metastatic melanoma therapy. Epigenetic reprogramming caused by increased histone deacetylase (HDAC) activity arising during tumor formation may contribute to resistance of melanomas to the alkylating drugs temozolomide, dacarbazine, and fotemustine. Here, we report on the impact of class I HDACs on the response of malignant melanoma cells treated with alkylating agents. The data show that malignant melanomas in situ contain a high level of HDAC1/2 and malignant melanoma cells overexpress HDAC1/2/3 compared with noncancer cells. Furthermore, pharmacologic inhibition of class I HDACs sensitizes malignant melanoma cells to apoptosis following exposure to alkylating agents, while not affecting primary melanocytes. Inhibition of HDAC1/2/3 caused sensitization of melanoma cells to temozolomide in vitro and in melanoma xenografts in vivo. HDAC1/2/3 inhibition resulted in suppression of DNA double-strand break (DSB) repair by homologous recombination because of downregulation of RAD51 and FANCD2. This sensitized cells to the cytotoxic DNA lesion O6-methylguanine and caused a synthetic lethal interaction with the PARP-1 inhibitor olaparib. Furthermore, knockdown experiments identified HDAC2 as being responsible for the regulation of RAD51. The influence of class I HDACs on DSB repair by homologous recombination and the possible clinical implication on malignant melanoma therapy with temozolomide and other alkylating drugs suggests a combination approach where class I HDAC inhibitors such as valproic acid or MS-275 (entinostat) appear to counteract HDAC- and RAD51/FANCD2-mediated melanoma cell resistance. Cancer Res; 76(10); 3067–77. ©2016 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HDAC1, HDAC2, and HDAC3 have been reported to be overexpressed in melanoma cells compared to primary melanocytes47”
From Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4 (2021) · cites this paper as [47]
In the citing paper
“HDAC inhibitors have been considered for usage in combinatorial therapies for several cancers including melanoma47,65–67.”
From Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4 (2021) · cites this paper as [47]
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302 · cited 1×
“Protein concentrations were determined using the Bradford method (26).”
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“29), and they express an oncogenic form of BRAF giving them a growth advantage (46).”
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · cited 1×
“Here, we addressed the contribution of class I HDACs in malignant melanoma protection against methylating chemotherapeutics, used, despite serine/threonine kinase inhibitors and immune-stimulating biologics (1, 3), as genotoxic `gold standard' in the therapy of this cancer.”
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“Here, we addressed the contribution of class I HDACs in malignant melanoma protection against methylating chemotherapeutics, used, despite serine/threonine kinase inhibitors and immune-stimulating biologics (1, 3), as genotoxic `gold standard' in the therapy of this cancer.”
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · cited 1×
“Although newer therapies targeting mutant B-Raf or immunotherapies with ipilimumab or anti-PD-1antibody have shown promise (1-3), the cancer invariably becomes resistant, which necessitates the switch back to genotoxic-based therapies.”
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887 · cited 3×
“As class I HDACs can deacetylate histones 3 (H3) and 4 (H4) (34), we determined whether inhibition of class I HDACs with valproic acid (VPA) (35) influences the acetylation level of H3 and H4 in melanoma lines (Fig.”
Self-citationMechanism of Eukaryotic Homologous Recombination
San Filippo, J., Sung, P., & Klein, H. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.061306.125255 · Cited by 1,681 · cited 1×
“As RAD51 and FANCD2 play central roles in HR (48), the downregulation of these HR proteins may therefore be responsible for the observed sensitization.”
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666 · cited 1×
“Although temozolomide, fotemustine, and IR induce different spectrums of DNA lesions, only HR is involved in the repair of all these genotoxins (47).”
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564 · cited 1×
“In cancer cells, the inhibition of HDACs has been shown to influence the execution of the extrinsic and intrinsic apoptosis pathways as well as affecting DNA repair (21).”
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404 · cited 1×
“Class I histone deacetylases (HDAC) have been described to be elevated in gastric, breast, colorectal, lung, and liver cancers (17, 18) and may contribute to those cancers' response to therapy.”
Cited by
Milazzo, G., Mercatelli, D., Di Muzio, G., Triboli, L., De Rosa, P., Perini, G., & Giorgi, F. M. (2020) · Genes · doi:10.3390/genes11050556 · Cited by 423
“Moreover, transcriptomic analyses on pancreatic cell models have confirmed the ability of VPA treatment in modify the epigenetic status (H3K9Ac) of cis regulatory elements of genes involved in cell cycle (cyclin D2) and metastatic cell behavior (Ccnd2) [239,240].”
BackgroundEpigenetic regulation of epithelial–mesenchymal transition
Sun, L., & Fang, J. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2303-1 · Cited by 159
“sues, another report reveals that inhibition of class I HDACs sensitizes malignant melanoma cells to apoptosis following temozolomide treatment [96].”
DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas
Kaina, B., & Christmann, M. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.04.007 · Cited by 150
Self-citationThe multifaceted influence of histone deacetylases on DNA damage signalling and DNA repair
Roos, W. P., & Krumm, A. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw922 · Cited by 139
“Ovaries (5), Lung (5), Pancreas (5), Thyroid (5), Prostate (15), Melanoma (16) HDAC3 Colorectal (5), Stomach (5), Oesophagus (5), Breast (5,11), Ovaries (5), Lung (5,21), Pancreas (5), Thyroid (5), Prostate (15)”
BackgroundInfluentialSelf-citationRole of Rad51 and DNA repair in cancer: A molecular perspective
Laurini, E., Marson, D., Fermeglia, A., Aulić, S., Fermeglia, M., & Pricl, S. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107492 · Cited by 141
Metadata
- Authors
- Krumm, A., Barckhausen, C., Kücük, P., Tomaszowski, K.-H., Loquai, C., Fahrer, J., Krämer, O. H., Kaina, B., & Roos, W. P.
- Affiliations
- Johannes Gutenberg University Mainz (DE)
- Venue
- Cancer Research
- Published
- 2016-05-12
- Volume
- 76
- Issue
- 10
- Pages
- 3067-3077
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2298649194
- Cited by
- 91
- References
- 55
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 2 · 2023: 9 · 2022: 5 · 2021: 15 · 2020: 14 · 2019: 6 · 2018: 12 · 2017: 9 · 2016: 6
- FWCI
- 5.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- German Research Foundation (RO3617)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- histone deacetylase, class I HDACs, HDAC1, HDAC2, HDAC3, melanoma, drug resistance, temozolomide, alkylating agents, RAD51, FANCD2, homologous recombination, DNA double-strand break repair, O6-methylguanine, synthetic lethality, PARP-1 inhibitors, olaparib, valproic acid, entinostat, epigenetic reprogramming, apoptosis
- MeSH terms
- Cutaneous Malignant Melanoma, Animals, DNA Repair, Fluorescent Antibody Technique, Histone Deacetylases, Humans, Immunoenzyme Techniques, Melanoma, RNA, Messenger, Skin, Skin Neoplasms, Tumor Cells, Cultured, Blotting, Western, Mice, SCID, Mice, Inbred NOD, Apoptosis, Drug Resistance, Neoplasm, Reverse Transcriptase Polymerase Chain Reaction, Xenograft Model Antitumor Assays, Cell Proliferation, Rad51 Recombinase, Mice, Fanconi Anemia Complementation Group D2 Protein, DNA Breaks, Double-Stranded, Histone Deacetylase Inhibitors, Homologous Recombination, Real-Time Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance. https://app.cochat.ai/papers/10.1158/0008-5472.can-15-2680
- The paper
- Krumm, A., Barckhausen, C., Kücük, P., Tomaszowski, K.-H., Loquai, C., Fahrer, J., Krämer, O. H., Kaina, B., & Roos, W. P. (2016). Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance. Cancer Research. https://doi.org/10.1158/0008-5472.can-15-2680
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.